Two-Step Purification of L-Asparaginase from Acrylaway® L

Autor(es)

Louise Lacalendola Tundisi ^[1] ; Diego de Freitas Coêlho ^[2] ; Alessandra Valéria de Sousa Faria ^[3] ; Adalberto Pessoa Junior ^[4] ; Elias Basile Tambourgi ^[5] ; Laura de Oliveira Nascimento ^[6] ; Edgar Silveira ^[7] ; Priscila Gava Mazzola ^[8]

Afiliação do(s) autor(es)

^[1] University of Campinas. Institute of Biology. Graduate Program in Biosciences and Technology of Bioactive Products - Brasil

^[2] University of Campinas. Chemical Engineering School - Brasil

^[3] University of Campinas. Institute of Biology. Department of Biochemistry and Tissue Biology - Brasil

^[4] University of São Paulo. Pharmaceutical Sciences School - Brasil

^[5] University of Campinas. Chemical Engineering School - Brasil

^[6] University of Campinas. Pharmaceutical Sciences School - Brasil

^[7] Federal University of Uberlândia. Genetics and Biochemistry Institute - Brasil

^[8] University of Campinas. Pharmaceutical Sciences School - Brasil

• Tipo de documento: Artigo Científico
• Fonte: Brazilian Journal of Pharmaceutical Sciences; v. 58, 2022-08-08.

Resumo

Abstract L-Asparaginase (L-ASNase) is a biopharmaceutical used for acute lymphoblastic leukaemia (ALL) treatment, dramatically increasing the patients’ chance of cure. However, its production and distribution in developing countries were disrupted because of its low profitability, which caused great concern among patients. This study evaluates the feasibility of combining fractional precipitation and aqueous two-phase systems (ATPS) to purify L-ASNase from a low-grade product, commercially known as Acrylaway® L. The ATPS purification results were not particularly expressive compared to the two-step purification process composed of ethanol precipitation and gel filtration, which was able to recover the target molecule with a purification factor over 5 fold. Thus, we studied a purification process capable of manufacturing pharmaceutical grade L-ASNase from a commercially available low-grade raw material; however, improvements regarding its throughput must be achieved, and high purity is the first step to apply it as a new biopharmaceutical product. The proposed process could pose as a short-time solution to mitigate its shortage while a cost-effective production plant is being developed. (AU)

• Processo FAPESP: 13/08617-7 - Produção de L-asparaginase extracelular: da bioprospecção à engenharia de um biofármaco antileucêmico
• Beneficiário: Adalberto Pessoa Junior
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 16/01869-9 - Bioprocessos alternativos de purificação de L-asparaginase terapêutica para leucemia linfoide aguda (LLA)
• Beneficiário: Louise Lacalendola Tundisi
• Modalidade de apoio: Bolsas no Brasil - Mestrado